. 2018 Apr 17;19:89. doi: 10.1186/s12882-018-0883-8

Table 2.

Visit schedule for REMOVAL-HD study

Study Phase	Screening	Wash in Period		Intervention							Wash out
Visits	Visit 1	Visit 2	Visit 3 Baseline	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8	Visit 9	Visit 10	Visit 11
	Week −1	Wk 0	Wk 4	Wk 6	Wk 8	Wk 12	Wk 16	Wk 20	Wk 24	Wk 28	Wk 32
Screening
Inclusion/exclusion criteria	X	X
Informed Consent	X
24 h Urine collection	X
Demographics/Medical History/Physical exam		X
Primary Outcome
Centrally tested serum albumin^a		X	X	X	X	X	X	X	X	X	X
Trial Intervention Use
High Flux (Revaclear) dialyser		X	X							X	X
Mid cut-off (Theranova) dialyser			X	X	X	X	X	X	X	X
Clinical assessments
Erythropoietin Resistance Index			X				X			X
Weight (pre & post HD)			X				X			X	X
Duration of HD			X				X			X	X
Restless Leg Symptom Rating Scale			X				X			X
Malnutrition Inflammation Score			X				X			X
Edmonton Symptom Assessment System Revised			X				X			X
6 min walk test^a			X				X			X
Adverse events (as required)		X	X	X	X	X	X	X	X	X	X
Local lab assessments
Albumin^a		X	X	X	X	X	X	X	X	X	X
Urea (pre & post HD)			X				X			X
Haemoglobin, transferrin, INR, APTT^a			X				X			X
Central lab samples
Lambda free light chains^a		X	X	X	X	X	X	X	X	X	X
Κappa-FLC, β2Microglobulin, high sensitivity C-Reactive Protein^a			X				X			X
Substudy – Matrix Gla Protein, fetuin A, CPP, FGF23^a			X				X			X

^a Collected pre-dialysis prior to the mid-week HD

APTT activated partial thromboplastin time, CPP calciprotein particles, FGF23 Fibroblast growth factor23, HD haemodialysis, INR international normalised ratio